A study published in Advanced Science reveals that TREM2+ macrophages contribute to immune dysfunction in endometriosis, compromising CD8+ T cell and NK cell cytotoxic behavior. Researchers identified TREM2 as a potential therapeutic target, suggesting new avenues for developing non-hormonal therapies for endometriosis.
Researchers developed a combination therapy approach using TargetScore algorithm to target PARP and SHP2 proteins, overcoming treatment resistance in breast cancer models. This approach showed durable responses and improved survival in multiple preclinical models.
A new study reveals that the CASS4 gene plays a crucial role in Alzheimer's disease by directing brain-cleaning immune cells, which can be disrupted leading to the buildup of toxic plaques. This discovery offers new hope for the development of treatments or prevention strategies by targeting the gene or microglia in the brain.
A new treatment approach combining immunotherapy with targeted cancer drug enfortumab vedotin improves survival in patients with muscle-invasive bladder cancer. The treatment reduces the risk of death by 42% and cancer recurrence or progression by 49% in patients unable to receive standard chemotherapy.
Researchers from UT MD Anderson Cancer Center presented promising advances in cancer immunotherapy at the 2026 SITC Annual Meeting, exploring new approaches to treating advanced cancers. These studies offer new insights to improve the effectiveness of immunotherapies and expand treatment options for patients.
The UVA Biotech Innovation Fund will support the SPARK Innovative Medicines program, helping to accelerate promising discoveries into new treatments and cures. The fund will provide long-term support for researchers to overcome the critical gap between discovery and clinical application.
Researchers have discovered how reprogrammed cancer cells can promote the formation of immune cells clusters that help coordinate the immune response, leading to better treatment outcomes for patients. The study's findings suggest that cell reprogramming could become a way to make tumors more responsive to immunotherapy.
A national program in Australia discovered that over 35% of infants initially diagnosed with a peanut allergy could safely have the diagnosis removed after undergoing an oral food challenge. This finding has significant implications for how Australia's healthcare system approaches infant food allergies.
Dr. El-Khoueiry is an international leader in liver cancer treatment and clinical trials. He will advance USC Norris' mission to translate scientific discoveries into new cancer prevention, diagnosis, and treatment approaches.
Researchers develop transdermal bioreactor patch to reprogram patient's own cells to fight disease or repair tissue, with potential applications in melanoma, diabetes, and autoimmune diseases. The technology aims to make advanced cell therapies faster, less costly, and available to more patients.
This study demonstrates that interleukin-33 alleviates the immunosuppressive tumor microenvironment in hepatocellular carcinoma, activating the STING/IRF axis and increasing functional CD8⁺ T cells. Combining IL-33 with anti-PD-L1 therapy synergistically reduces tumor burden and boosts anti-tumor immunity in vivo.
A new study published in Cell reveals that perforin, a protein made by T cells and NK cells, can induce ferroptosis in tumor cells, a previously unknown mechanism of cell death. This discovery could have significant implications for understanding how cancers are killed by immune cells and could lead to new avenues for immunotherapy.
Researchers at UCLA Health Jonsson Comprehensive Cancer Center identified a new strategy to strengthen immune cells and improve their ability to kill cancer cells. Temporarily activating p53, a protein that prevents cancer, helps engineered immune cells resist exhaustion and improve their ability to kill tumor cells.
Primary biliary cholangitis is a chronic autoimmune disease destroying small bile ducts inside the liver, causing inflammation and fibrosis. The peribiliary immune niche model explains disease development into three overlapping processes: immune initiation, effector amplification, and regulatory failure.
Researchers developed a diet-based mouse model to study a serious immunotherapy side effect affecting up to 40% of patients. The study found that a protein in unstable immune cells can cause inflammation, which can be reversed by shutting off the protein or switching to a high fiber diet.
A new review examines how gut microbiota and metabolites reshape liver immunity and propose strategies to overcome immunotherapy resistance. The review discusses four major directions of gut microbiota intervention, including probiotics, fecal microbiota transplantation, engineered bacteria, and metabolite-based interventions.
Melanie Ott and Alex Marson, directors at Gladstone Institutes, have been elected to the National Academy of Medicine for their pioneering achievements in science and medicine. Their work focuses on understanding viral mechanisms, developing innovative treatments, and repurposing human immune cells to fight disease.
Researchers from the University of Osaka have uncovered the first steps in the development of ANCA-associated glomerulonephritis, a kidney disease triggered by ANCAs. They found that injured kidney cells send signals attracting immune cells, including neutrophils, which drive inflammation in the early stages.
Researchers developed a gene-editing platform to make cell therapies more practical for patients with complex immune conditions. The platform uses prime editing to make therapeutic T cells resistant to immunosuppressive drugs, allowing clinicians to selectively boost or suppress them.
DS1025, a CD25-directed antibody drug conjugate, targets immunosuppressive regulatory T cells in the tumor microenvironment, aiming to reduce a mechanism that can limit the body's immune response against cancer. The trial is an international effort to investigate DS1025 in patients with advanced solid tumors.
The Phase 1b FURTHER trial revealed that firmonertinib achieved durable antitumor activity in patients with EGFR PACC-mutated non-small cell lung cancer, with 43% and 68% objective response rates at 160mg and 240mg daily doses, respectively. Patients with complete clearance of EGFR PACC mutations from their blood experienced higher res...
Charité has established a new HIV cure research center, BeCURE, to improve the outlook for people living with HIV. The center aims to develop targeted antibody, immune, cell, and gene therapies to eliminate or keep the virus in check.
This comprehensive review synthesizes molecular mechanisms, current therapeutics, and emerging strategies in esophageal cancer. The findings highlight breakthroughs in immunotherapy and promising future directions in targeted therapies.
UChicago Medicine launches a groundbreaking clinical trial testing a new personalized cell therapy for advanced solid tumors, including ovarian cancer and melanoma. The treatment uses specially engineered T-cell receptors to detect hidden cancer proteins, expanding the number of cancers that can be targeted.
Researchers developed a GRM4-targeted lipoplex to generate NKG2D CAR T/NK cells within triple-negative breast cancer, eliminating the need for cells to reach their target. The approach improved safety and antitumor efficacy, increasing CD8+ T cell infiltration, NK cell activation, and tumor growth inhibition.
Researchers found that specific combinations of TP53 and CDKN2A mutations activate cGAS-STING-mediated immunity, delaying oral cancer progression. The immune activation was associated with delayed progression to invasive oral cancer.
An international team identified ST6GAL1 as a key driver of glycocalyx remodeling, which shifts macrophages from an immunosuppressive state to a tumor-fighting state. Suppression of ST6GAL1 inhibited tumor growth in laboratory co-cultures, suggesting a potential strategy for cancer immunotherapy.
The review proposes co-designing oncolytic viruses and CAR cells to overcome solid tumor barriers, enabling a self-amplifying therapeutic system. Oncolytic viruses can be engineered to deliver payloads, expanding target recognition and maintaining CAR cell function.
Chemotherapies like CarboTaxol enhance cancer vaccine responses by expanding a pool of T cells that express the factor TCF1, rejuvenating their life and functionality. This effect is further enhanced when combined with immunotherapy, showing potential for improved clinical trial outcomes.
Researchers at UT MD Anderson Cancer Center have made significant breakthroughs in cancer treatment, developing a targeted antibody that improves outcomes for patients with advanced lung cancer who have faced treatment resistance. The treatment, which combines ivonescimab with chemotherapy, has been shown to extend disease control and ...
Researchers are exploring biomarker-guided patient selection and combination therapies to overcome glioblastoma's biological barriers. Agents targeting tumor metabolism, immunotherapies, and oncolytic viruses are being investigated.
In vivo CAR-T therapy reduces manufacturing time and cost, enabling more accessible cancer immunotherapy. The strategy also enables superior self-renewal capacity and anti-tumor persistence.
Researchers developed an AI model that uses routine chest CT scans to identify patients at risk of pneumonitis, a potentially life-threatening form of lung inflammation. The model, called CIPHER, achieved high predictive power and maintained strong performance despite differences in patient populations and imaging protocols.
A retrospective analysis of 20,000 patient records found that patients receiving immunotherapy and multiple immunosuppressive therapies were at higher risk of severe infections. Treatment with multiple immunosuppressive therapies was associated with increased rates and severity of infection.
Scientists found that the gene ZMYND8 drives T-cell exhaustion, revealing a new strategy to improve anti-tumor and anti-viral immune responses. Removing ZMYND8 improves anti-tumor and anti-viral responses on its own, and shows potential synergy in combination with immunotherapy.
Researchers at Bar-Ilan University and Weizmann Institute successfully engineered immune cells to recognize and attack cancer and viral targets. The enhanced T cells demonstrated stronger immune responses and greater cancer-killing ability, improving survival in mice.
Researchers identified a previously unknown pathway that prostate tumors leverage to suppress the immune system, reshaping the tumor microenvironment to resist treatment. Combining B7-H3-targeted therapy with MEK inhibition improved antitumor responses and prolonged survival in preclinical models of castration-resistant prostate cancer.
Research by Professor Dong Zhang's team identifies IFITM1 as a key regulator of mitophagy, essential for maintaining the anti-tumor activity of double-negative T cells. This mechanism provides a promising strategy for optimizing TCRαβ+CD4-CD8- T cell therapies.
Hepatocellular carcinoma (HCC) cells upregulate lipid uptake, de novo lipogenesis, and fatty acid oxidation, supporting tumour growth and metastasis. Targeting lipid metabolism, including CE synthesis and lipid biosynthetic enzymes, shows synergistic effects with antitumour drugs.
The new guidelines, developed by leading experts, focus on improving sepsis care by strengthening systems for diagnosis, treatment, prevention, and quality improvement. Emerging technologies, such as next-generation diagnostics and artificial intelligence, are also being explored to enhance sepsis care.
Researchers identified a link between B cell activity and immunotherapy-related colitis, a common side effect of cancer treatments. Higher B cell levels before treatment were associated with increased colitis risk, and depleting B cells reduced colitis severity.
Researchers have developed a computational framework to design and fabricate crisscross DNA megastructures, expanding accessibility to DNA nanotechnology. This breakthrough enables the construction of complex structures with precise control, opening up new avenues for applications in fields like optics, immunology, and tissue engineering.
UCLA researchers are launching a phase 1/2 clinical trial to evaluate the safety and efficacy of JAK inhibitors in preventing immune checkpoint inhibitor-induced type 1 diabetes. The trial aims to test whether these drugs can protect insulin-producing cells in patients who develop diabetes after cancer immunotherapy.
A new review in Science Bulletin outlines how multimodal AI can integrate molecular, cellular, and clinical data to refine treatment choices and predict side effects. The approach aims to address challenges in cancer treatment, including primary resistance and immune-related adverse events.
Salk Institute researchers have discovered a novel pathway that links chronic interferon II exposure to mitochondrial dysfunction, leading to immunosuppression and enhanced tumor growth. By blocking prostaglandin E2, they found a viable target to restore immune system function and combat immunotherapy resistance.
The study confirms the durability of benefit for pembrolizumab plus chemotherapy as a first-line standard-of-care option for recurrent and metastatic cervical cancer. This treatment regimen has been shown to provide a significant advantage over traditional chemotherapy in patients with this type of cancer.
Acute myeloid leukemia (AML) remains difficult to treat with immunotherapy due to its ability to evade the immune system. The study aims to understand how immune cells recognize leukemia cells without relying on HLA, with the goal of developing HLA-independent immunotherapies.
Researchers found that pancreatic cancer cells create localized immune-protective niches that shield tumors from immune attack. Disrupting these protective mechanisms slowed tumor growth and improved responses to immunotherapy in preclinical models.
Researchers found that methylglyoxal stress stimulates the expansion of immunosuppressive cells, which can help cancer evade immune surveillance. The study also identified a potential biomarker for predicting response to immunotherapy.
The 2026 Josep Carreras Institute Symposium explores the latest immunology advances in haematological malignancies, transforming treatment landscapes with CAR-T therapies and checkpoints. Major challenges remain in understanding tumour-immune system interactions and therapeutic resistance.
Researchers discovered that cancer cells use an antioxidant protein to suppress T cells, allowing them to evade the immune system. This finding identifies a promising new target for cancer immunotherapy, potentially helping to overcome treatment resistance and improve patient outcomes.
Children's Hospital Colorado has launched a Sublingual Immunotherapy Program to treat children with 10 common food allergies, including milk, egg, peanut, and sesame. The program involves daily liquid drops under the tongue and may gradually build tolerance and provide greater protection against accidental exposure.
Prostate cancer affects 1 in 8 men, with 60% diagnosed in men 65 and older. Clinical trials like Alliance's help improve early detection and treatment, reducing mortality rates by half since 1993. These trials also explore new treatments and survivorship strategies.
Immunotherapy for gynecological tumors offers durable responses and survival benefits, but complex immune evasion mechanisms and tumor microenvironment pose challenges. Current treatment options, such as ICIs and adoptive cell therapy, show promise, but precision immunotherapy is needed to improve patient outcomes.
Tumor-infiltrating lymphocyte therapy has shown potential in several types of solid tumors, including metastatic melanoma, breast cancer, and ovarian cancer. Despite challenges, the approach has favorable clinical outcomes, and researchers are exploring combination strategies and advanced technologies to improve treatment durability.
Researchers developed tools to compare tumor microenvironments and predict treatment response by analyzing spatial transcriptomic data. The new tools provide a detailed map of tumor cell organization, enabling clinicians to quickly analyze and compare tumor 'floor plans' and determine the best course of treatment.
Researchers discovered how tumors interact with the body to grow and spread, revealing a new target for cancer therapy. Metadherin, a protein encoded by the MTDH gene, mediates this metabolic-immune crosstalk, supporting tumor growth and metastasis.
UCSF scientists have invented a way to treat cancer with teacher cells and tumor pieces, combining immune cells grown in the lab with patient tumor samples. The method uses dendritic cells to train T cells to recognize and destroy cancer cells, offering a promising approach to immunotherapy.
A new study from Arizona State University finds that past immune encounters can predict future vaccine response, opening a path toward more personalized vaccination strategies. Researchers analyzed blood samples from over 4,000 people, identifying antibody signatures that distinguish strong responders from weak ones.
Researchers discovered that exhausted T cells can lose the exhaustion marker LAG3 to escape tumors and confer long-lasting immunity to cancer in mice. These cells play a critical role in generating a strong, durable memory response, which is essential for effective cancer immunotherapy.